Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29472170 | 0.88 | — | — | |
| Water SCHEMBL28147067 | 0.85 | — | — | |
| SCHEMBL20532 | 0.85 | — | — | |
| SCHEMBL112370 | 0.82 | CA1 (0.38) | — | |
| SCHEMBL21237759 | 0.82 | CA1 (0.38) | — | |
| SCHEMBL1472301 | 0.82 | CA1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL1162671 | 0.82 | — | — | |
| Ammonia Solution, Strong SCHEMBL8078551 | 0.82 | — | — | |
| SCHEMBL607695 | 0.82 | CA1 (0.38) | — | |
| SCHEMBL40788 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207723-A1 | UNSATURATED HYDROCARBON PYRIMIDINE THIOETHER COMPOUNDS AND PREPARATION METHOD AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY OF TECHNOLOGY (CN) | 2020-07-02 | — | — | US | claimed |
| EP-3321271-B1 | METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | JAPAN TOBACCO INC (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-29 | — | — | US | disclosed |
| US-20210154148-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-05-27 | — | — | US | disclosed |
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MordernaTX, Inc. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10822354-B2 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof | JAPAN TOBACCO INC. (JP) | 2020-11-03 | — | — | US | disclosed |
| US-20190314292-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2019-10-17 | — | — | US | disclosed |
| EP-3321271-A1 | METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | Japan Tobacco, Inc. (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154148-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | SLC6A4 4487/4885SLC6A3 3995/4885 |
| US-10857105-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | SLC6A4 4487/4885SLC6A3 3995/4885 |
| US-20200207723-A1 | UNSATURATED HYDROCARBON PYRIMIDINE THIOETHER COMPOUNDS AND PREPARATION METHOD AND APPLICATION THEREOF | DHFR, AHR, DDT | SLC6A4 4744/4885SLC6A3 4859/4885 |
| US-10822354-B2 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof | JAK1, JAK3, JAK2 | SLC6A4 2883/4885SLC6A3 2658/4885 |
| US-20190314292-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | SLC6A4 4487/4885SLC6A3 3995/4885 |
| US-20220409536-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | SLC6A4 4487/4885SLC6A3 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.